ArticleFrontiers in oncology2022

PD-1 inhibitors plus lenvatinib versus PD-1 inhibitors plus regorafenib in patients with advanced hepatocellular carcinoma after failure of sorafenib.

Yongkang Xu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.